Navigation Links
Prix Galien USA Announces 2008 Final Candidates
Date:8/12/2008

Honorees for best pharmaceutical agent and best biotechnology product to be recognized at Sept. 24 gala ceremony

NEW YORK, Aug. 12 /PRNewswire-USNewswire/ -- The Prix Galien USA 2008 (http://www.prix-galien-usa.com) will recognize innovative biopharmaceutical drugs and devices that have made a deep impact on the quality of human life in ways that range from providing treatment for cancer and HIV/AIDS to hypertension and chronic pain. Charlie Rose will again emcee the awards ceremony on September 24, 2008, to be held at the American Museum of Natural History in New York.

The final candidates for the Prix Galien USA 2008 awards are:

-- Actelion Ltd. - Ventavis(R) (Iloprost)

-- Alexion Pharmaceuticals - Soliris(TM)

-- BioMarin Pharmaceutical Inc. - Nagalzyme(R)

-- Bristol-Myers Squibb - Sprycel(R)

-- Boehringer Ingelheim - Aptivus(R) and Spiriva(R)

-- Celgene Corporation - Revlimid(R)

-- CV Therapeutics Inc. - Ranexa(R) (ranolazine)

-- Elan Corporation - Prialt(R) (ziconotide intrathecal infusion)

-- Eli Lilly Company - Evista(R) raloxifene HCI

-- Genzyme Corporation - Myozyme(R)

-- GlaxoSmithKline - Tykerb(TM) (lapatinib) and Altabax(TM) (retapamulin ointment)

-- Merck & Co. - Isentress(R) (raltegravir)

-- Novartis AG - Exjade(R) (deferasirox) and Tekturna(R)

-- Nycomed - Omnaris

-- Pfizer Inc. - Selzentry(TM)

-- Roche Laboratories Inc. - Boniva(R)

-- sanofi-aventis - Lovenox(R)

-- Sanofi Pasteur - H5N1 influenza virus vaccine

-- Sucampo Pharmaceuticals, Inc. - Amitiza(R)

-- Wyeth - Infuse/InductOs (rh BMP-2 dibotermin alfa) Torisel (temsirolimus) Injection.

"Nominees for the Prix Galien USA stand apart from other drugs in the marketplace for the amount of research and level of skill that was invested to develop these innovative medicines that improve lives," said Gerald Weissmann, M.D., Prix Galien USA committee chair, New York University professor emeritus and editor-in-chief of The FASEB Journal.

At the awards ceremony The Population Council and Sheldon Segal, distinguished scientist at the organization, will receive the Prix Galien USA 2008 Pro Bono Humanum Award along with other members of the coalition -- Wyeth, Dow Corning and the late Judah Folkman of Harvard University -- that made possible the development and distribution of implantable hormone delivery systems that are used for birth control and family planning purposes by more than 8 million women worldwide.

The Prix Galien USA Awards (http://www.prix-galien-usa.com) committee of 11, including 7 Nobel Laureates, recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines that improve the human condition, and is considered the industry's highest accolade for pharmaceutical research and development -- equivalent to the Nobel Prize.


'/>"/>
SOURCE Prix Galien USA
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
2. Concentric Medical(R) Announces Co-Marketing Agreement With InTouch Health(R) to Advance Acute Ischemic Stroke Care
3. Bion Announces Approval of New U.S. Patent for Phosphorus Removal Process for Livestock Waste Environmental Treatment
4. Telik Announces Financial Results For 2008 Second Quarter
5. Mergent, Inc. Announces Changes to the HealthShares(TM) European Drugs Index
6. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
7. Genaera Corporation Announces Second Quarter Financial Results
8. China Biologic Products Announces Second Quarter 2008 Results Conference Call
9. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
10. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... Vixiar Medical announced today ... manufacturing functions to The LaunchPort™ Accelerator at the City Garage in Port Covington. ... manufacturing and business services to its Residents. , Vixiar Medical recently closed ...
(Date:9/21/2017)... ... 21, 2017 , ... Today, BioPharma Institute, a leading training ... of 5 new courses to its prospectus. These include the eagerly-awaited Regulation ... 11 on Electronic Records and Electronic Signatures (Part 11 of Title 21 of ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... has appointed Vishwas Paralkar to the role of chief scientific officer. In this ... will report to Cybrexa’s president and CEO, Per Hellsund. , “I was impressed ...
(Date:9/20/2017)... ... September 20, 2017 , ... From industry leaders, sports stars, and Hollywood ... failed. Many of these people had lost all hope. Their stories are ... Download (pdf) , “Neil takes readers on a riveting journey through the ...
Breaking Biology Technology:
(Date:4/24/2017)... , April 24, 2017 Janice ... partner with  Identity Strategy Partners, LLP (IdSP) , ... or without President Trump,s March 6, 2017 ... Entry , refugee vetting can be instilled with greater ... (Right now, all refugee applications are suspended by ...
(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced Design ... will feature emerging and evolving technology through its ... Summits will run alongside the expo portion of the ... panels and demonstrations focused on trending topics within 3D ... design and manufacturing event will take place June 13-15, 2017 ...
Breaking Biology News(10 mins):